
Repligen Acquires 908 Devices’ Bioprocessing Analytics Portfolio for $70 Million
Repligen Acquires 908 Devices’ Bioprocessing Analytics Portfolio for $70 Million Repligen Corporation (Nasdaq: RGEN), a leading life sciences company specializing in bioprocessing technology, has announced the acquisition of 908 Devices Inc.’s (Nasdaq: MASS) desktop portfolio, further strengthening its position in…